-
<![CDATA[Breaking Down The SUNMO Trial on M-Pola in ASCT-Ineligible R/R LBCL]]>
25 Sep 2025 03:51 GMT
… ) compared with rituximab (Rituxan) plus gemcitabine and oxaliplatin (R-GemOx) in … associate professor of medicine at The Warren Alpert Medical School of Brown … ] first-line treatment. This trial, [unlike] some other recently reported trials, enrolled high …
-
<![CDATA[Alnodesertib Receives FDA Fast Track Designation For ATM– Metastatic CRC]]>
24 Sep 2025 17:03 GMT
… medical officer of Artios, said in the news release on the FDA … deliver meaningful benefit where treatment options are limited.” … with irinotecan or gemcitabine. Gemcitabine was given on … STELLA trial, the developers are conducting expansion trials in …
-
<![CDATA[Dr Dotan on Gemcitabine and Nab-Paclitaxel in Treatment-Naive, Older Pancreatic Cancer]]>
23 Sep 2025 23:32 GMT
… Barshinger Cancer Institute at Penn Medicine Lancaster General Health, discusses the … ECOG-ACRIN EA2186 (GIANT) trial (NCT04233866) evaluating gemcitabine and nab-paclitaxel (Abraxane … leading to patients receiving less treatment while still achieving the same …
-
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
25 Sep 2025 12:30 GMT
… and cancer treatments delivered with … Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical … RenovoCath with gemcitabine received Orphan Drug Designation for … property development, clinical trials, our therapy platform …
-
Experts react to FDA approval of gemcitabine intravesical system in NMIBC
22 Sep 2025 23:55 GMT
… 9, 2025, the FDA approved the gemcitabine intravesical system (Inlexzo; … drug releasing system to provide extended local delivery of a cancer medication … for 3 weeks per treatment cycle for up to … data from the SunRISe-1 trial (NCT04640623), which showed …
-
Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer
23 Sep 2025 01:01 GMT
… -stage trial of the drug in the first-line treatment of … arm of Elraglusib plus Gemcitabine/nab-paclitaxel (GnP … . Food and Drug Administration (FDA) and the European Medicines Agency (EMA) … cancer with three ongoing trials in combination with current …
-
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
22 Sep 2025 12:45 GMT
… Phase 2 trial in first-line treatment of metastatic … arm of elraglusib plus gemcitabine/nab-paclitaxel … Food and Drug Administration (FDA) and the European Medicines Agency (EMA … competition from other biotechnology and pharmaceutical companies; our ability …
-
<![CDATA[Managing AEs with Gemcitabine Intravesical System in NMIBC]]>
20 Sep 2025 20:09 GMT
… the phase 2 SunRISe-1 trial (NCT04640623) data indicated a … it’s only delivering a drug for 1 week out … symptoms] with the [gemcitabine intravesical system] vs other trials. Symptoms of the … 70s and 80s with multiple medications or an overactive bladder does …
-
Experts discuss chemoablation and evolving NMIBC strategies
24 Sep 2025 22:45 GMT
… value of preventive treatment. Others acknowledged that … bladder.
Panelists reviewed trial details: 240 patients … approval for new drugs, and Medicare coverage requires … intravesical chemotherapy, particularly gemcitabine. Many clinicians administer …
-
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
24 Sep 2025 20:01 GMT
… -party MPACT pivotal trial data for gemcitabine/nab-paclitaxel … new category of cancer medicines, Deep Cyclic Inhibitors. … our product candidates; the treatment potential of Deep Cyclic … to conduct our clinical trials, manufacture our product candidates …
About
© 1995-2025